MELBOURNE, Australia, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (OTCQB:IMROY) is pleased to announce that the company has executed a partnership agreement with TravelCare WorldWide LLC (TravelCare) of Lone Tree, Colorado for the sale of Travelan throughout its travel medicine network. The specific terms and conditions of this agreement will remain confidential.
TravelCare is a Group Purchasing Organization (GPO) buying group and a provider of travel medicine, immunization and vaccination services in North America. With 70+ travel clinic locations, exceptional experience of combined nursing and medical care, TravelCare has a high level commitment of care for their patients. They offer fully mobile healthcare services to companies, schools, churches and other organizations that require immunizations, vaccinations and other healthcare needs, thereby saving time and money to their clients.
TravelCare was founded in 2004 by John Broach. They are a member of the International Society of Travel Medicine and have access to over 2,000 members worldwide, who are available to provide first-hand information specific to an area that can’t be accessed from the CDC, or World Health Organization.
The President and founder of TravelCare WorldWide, John Broach said;
“Travel Care WorldWide is a leader in the field of international travel vaccines and other protective products for travelers who have visited all seven continents. We are extremely pleased to add Travelan to our suite of products and enter into this very promising partnership with Immuron. The real winners will be the traveling public.”
Immuron CEO Thomas Liquard added;
“We are excited to be able to offer Travelan through TravelCare. They are leaders in the travel medicine clinic industry and we look forward to building a productive and long-term relationship.
This is another win for Travelan in the US and a clear indication of Travelan’s outstanding value proposition. This agreement is in-line with our commitment to our shareholders, to maximize our presence throughout the US.”
Travelan’s active ingredient is Hyperimmune Bovine Colostrum Powder which is a rich source of antibodies that bind to Enterotoxigenic E. coli in the gastrointestinal tract preventing them from attaching to the intestinal wall and thereby neutralizing their ability to cause Travelers’ Diarrhea and its associated symptoms. Hyperimmune Colostrum is developed under Immurons' Proprietary Technology to create high titers of antibodies to a range of E- Coli bacteria that is present in normal colostrum in very small amounts.
Immuron Ltd (ASX:IMC) (OTCQB:IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The company currently markets Travelan® for the prevention of travellers’ diarrhoea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs.
Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), Monash University (Australia) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia).
Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.
Thomas Liquard Chief Executive Officer AUS Ph: +61 (0)3 9824 5254 email@example.com Immuron Investor Relations: Jon Cunningham RedChip Companies, Inc. (407) 644-4256, ext. 107 firstname.lastname@example.org